INT139237

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 23
Total Number 23
Disease Relevance 24.31
Pain Relevance 1.28

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (CDH1) cell adhesion (CDH1) Golgi apparatus (CDH1)
plasma membrane (CDH1) cytoplasm (CDH1)
Anatomy Link Frequency
enterocytes 2
plasma 2
basal areas 2
lung 2
appendix 2
CDH1 (Homo sapiens)
Pain Link Frequency Relevance Heat
metalloproteinase 21 99.70 Very High Very High Very High
Pain 19 98.08 Very High Very High Very High
COX-2 inhibitor 14 95.20 Very High Very High Very High
Inflammation 97 89.52 High High
fibrosis 70 78.56 Quite High
Deep tissue 2 74.88 Quite High
imagery 16 72.16 Quite High
palliative 4 68.64 Quite High
COX2 4 68.44 Quite High
Somatostatin 5 60.32 Quite High
Disease Link Frequency Relevance Heat
Carcinoma 275 99.98 Very High Very High Very High
Metastasis 156 99.92 Very High Very High Very High
Skin Cancer 59 99.84 Very High Very High Very High
Targeted Disruption 14 99.80 Very High Very High Very High
Cancer 1134 99.66 Very High Very High Very High
Endometrial Cancer 459 99.56 Very High Very High Very High
Acute Renal Failure 83 99.42 Very High Very High Very High
Aggression 14 99.32 Very High Very High Very High
Burns 74 99.20 Very High Very High Very High
Stomach Cancer 195 98.84 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The biochemical changes associated with over-expression of COX-2 include increased expression and activation of metalloproteinase-2 (MMP-2) and reduced expression of E-cadherin [102-104].
Negative_regulation (reduced) of Gene_expression (expression) of E-cadherin associated with metalloproteinase
1) Confidence 0.57 Published 2003 Journal Mol Cancer Section Body Doc Link PMC149414 Disease Relevance 0.91 Pain Relevance 0.09
In endometrial carcinoma, partial or complete loss of E-cadherin expression correlates with aggressive behavior [9].
Negative_regulation (loss) of Gene_expression (expression) of E-cadherin associated with aggression and endometrial cancer
2) Confidence 0.51 Published 2010 Journal Obstetrics and Gynecology International Section Body Doc Link PMC2846683 Disease Relevance 1.82 Pain Relevance 0
A hallmark of epithelial-mesenchymal transition is loss of E-cadherin expression.
Negative_regulation (loss) of Gene_expression (expression) of E-cadherin
3) Confidence 0.51 Published 2010 Journal Obstetrics and Gynecology International Section Body Doc Link PMC2846683 Disease Relevance 0.55 Pain Relevance 0
Decreased expression of E-cadherin is frequent in endometrial carcinoma and may be caused by LOH or promotor hypermethylation.
Negative_regulation (Decreased) of Gene_expression (expression) of E-cadherin associated with endometrial cancer
4) Confidence 0.51 Published 2010 Journal Obstetrics and Gynecology International Section Body Doc Link PMC2846683 Disease Relevance 1.45 Pain Relevance 0
The main hallmark of this process is the loss of E-cadherin expression mainly caused by repressed transcription of this gene (CDH1) [2].
Negative_regulation (loss) of Gene_expression (expression) of E-cadherin
5) Confidence 0.44 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2680015 Disease Relevance 0.83 Pain Relevance 0
Loss or reduction of the E-cadherin and beta-catenin expressions and overexpression of CD44s in the round cells are suggested to be contributed to the high propensity for lymphatic permeation and poor prognosis.
Negative_regulation (reduction) of Gene_expression (expressions) of E-cadherin
6) Confidence 0.29 Published 2006 Journal Virchows Arch. Section Abstract Doc Link 17033799 Disease Relevance 0.79 Pain Relevance 0.07
Overall, an inverse relationship was noted between FAK and E-cadherin expression (Additional File 3: A).
Negative_regulation (noted) of Gene_expression (expression) of E-cadherin
7) Confidence 0.15 Published 2010 Journal BMC Clin Pathol Section Body Doc Link PMC2829523 Disease Relevance 1.20 Pain Relevance 0
In addition, studies have shown that the expression of E-Cadherin is uniformly present in healthy gums, but decreased expression of the protein were found in the basal areas of the oral gingival epithelium in diseased samples [9].
Negative_regulation (decreased) of Gene_expression (expression) of E-Cadherin in basal areas
8) Confidence 0.14 Published 2010 Journal J Transl Med Section Body Doc Link PMC2998472 Disease Relevance 1.81 Pain Relevance 0.22
Decreased E-Cadherin expression is characteristic of cancer, including lung, prostate, gastric cancers as well as colorectal carcinoma and breast cancer [8].
Negative_regulation (Decreased) of Gene_expression (expression) of E-Cadherin in lung associated with cancer, breast cancer, colon cancer and stomach cancer
9) Confidence 0.14 Published 2010 Journal J Transl Med Section Body Doc Link PMC2998472 Disease Relevance 2.21 Pain Relevance 0.26
Burns septic ARF group plasma also induced a decreased expression of E-cadherin and pan-cytokeratin epithelial markers (data not shown) and of the tight junction protein ZO-1 (Figure 5G–I).


Negative_regulation (decreased) of Gene_expression (expression) of E-cadherin in plasma associated with acute renal failure and burns
10) Confidence 0.09 Published 2008 Journal Crit Care Section Body Doc Link PMC2447585 Disease Relevance 1.93 Pain Relevance 0.03
-catenin activity is enhanced at the invasive front, where the expression of E-cadherin, a direct target of Snail, is downregulated [53], suggesting that this positive regulatory signaling is functional in vivo.
Negative_regulation (downregulated) of Gene_expression (expression) of E-cadherin
11) Confidence 0.07 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2908545 Disease Relevance 0.97 Pain Relevance 0
Significant ET-1-induced mRNA expression of the transcription factor Snail, which has been identified a potent inhibitor of E-cadherin expression in melanoma, closely correlates with downregulation of E-cadherin.
Negative_regulation (inhibitor) of Gene_expression (expression) of E-cadherin associated with skin cancer
12) Confidence 0.07 Published 2004 Journal J Transl Med Section Body Doc Link PMC436068 Disease Relevance 0.86 Pain Relevance 0.14
Additionally, activation of ETBR pathway by ET-1 and ET-3 contributes to disruption of normal host-tumor interactions by downregulating the expression of E-cadherin and associated ?
Negative_regulation (downregulating) of Gene_expression (expression) of E-cadherin associated with cancer
13) Confidence 0.07 Published 2004 Journal J Transl Med Section Body Doc Link PMC436068 Disease Relevance 0.95 Pain Relevance 0.12
In pagetoid spread lesions and in situ carcinomas E-cadherin immunoexpression was also shown to be reduced or absent.23 However, one should be aware that E-cadherin expression is not always reduced or absent, depending on the mutation localisation and specific mechanisms of inactivation of the wild type allele.


Negative_regulation (reduced) of Gene_expression (expression) of E-cadherin associated with carcinoma
14) Confidence 0.06 Published 2010 Journal Journal of Medical Genetics Section Body Doc Link PMC2991043 Disease Relevance 0.70 Pain Relevance 0
In addition, E-cadherin expression is reduced, resulting in compensatory expression of N-cadherin (N-cad).
Negative_regulation (reduced) of Gene_expression (expression) of E-cadherin associated with coronary artery disease
15) Confidence 0.05 Published 2007 Journal Cell Mol Life Sci Section Body Doc Link PMC2775119 Disease Relevance 1.03 Pain Relevance 0
E-cadherin immunoexpression has been shown to be reduced or absent in early invasive gastric carcinomas, contrasting with the normal membranous E-cadherin expression in adjacent non-neoplastic mucosa, in keeping with a clonal origin of the cancer foci.
Negative_regulation (reduced) of Gene_expression (immunoexpression) of E-cadherin associated with cancer and stomach cancer
16) Confidence 0.04 Published 2010 Journal Journal of Medical Genetics Section Body Doc Link PMC2991043 Disease Relevance 0.96 Pain Relevance 0
In pagetoid spread lesions and in situ carcinomas E-cadherin immunoexpression was also shown to be reduced or absent.23 However, one should be aware that E-cadherin expression is not always reduced or absent, depending on the mutation localisation and specific mechanisms of inactivation of the wild type allele.


Negative_regulation (reduced) of Gene_expression (immunoexpression) of E-cadherin associated with carcinoma
17) Confidence 0.04 Published 2010 Journal Journal of Medical Genetics Section Body Doc Link PMC2991043 Disease Relevance 0.73 Pain Relevance 0
inhibition with LiCl and an additive or synergistic effect on E-cadherin expression with both inhibitors [130].
Negative_regulation (inhibition) of Gene_expression (expression) of E-cadherin
18) Confidence 0.03 Published 2006 Journal Invest New Drugs Section Body Doc Link PMC2780666 Disease Relevance 0.55 Pain Relevance 0
E-cadherin governs cell-cell contact and reduced expression of E-cadherin allows cells to separate from their neighbors and invade locally and distantly.
Negative_regulation (reduced) of Gene_expression (expression) of E-cadherin
19) Confidence 0.03 Published 2006 Journal Radiat Oncol Section Body Doc Link PMC1764894 Disease Relevance 0.84 Pain Relevance 0
While gerbils turned out to be a natural host for L. monocytogenes, a transgenic mouse line was developed that features expression of human E-cadherin in enterocytes [49].
Negative_regulation (developed) of Gene_expression (expression) of E-cadherin in enterocytes associated with targeted disruption
20) Confidence 0.02 Published 2010 Journal International Journal of Inflammation Section Body Doc Link PMC3003996 Disease Relevance 0.24 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox